why choose us

First received: March 22, 2023

Clinical Trial: ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Colorectal Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase 1b Study of the OxPhos Inhibitor ME-344 Combined With Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Brief Summary: This is a Phase 1b open-label, multiple dose/schedule sequential study to determine the safety and efficacy of the oxidative phosphorylation (OxPhos) pathway inhibitor ME-344 in combination with bevacizumab in subjects with recurrent mCRC.

Read more